The boom of copyright’s drug initially ignited significant progress in the drug sector, producing a perception of easy gains. However, funding in companies solely reliant on flagship drugs like the erectile dysfunction pill presents substantial dangers. Patent expiration has led alternative competition, eroding market portion and likely lowering

The recent surge in investments into boutique pharmaceutical companies, particularly those focusing on novel therapies and challenging drug development programs, has fueled what some are calling "High Investor Pharma." While the possibility for blockbuster treatments and significant returns is certain, the connected risks are also considerable. Man